Sloy Dahl & Holst’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sloy Dahl & Holst’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Buy	2,008 +1	+0%	+$135	0.04%	89
2026 Q1	$256K	Hold	2,007	–	–	0.04%	95
2025 Q4	$245K	Buy	2,007 +4	+0.2%	+$459	0.03%	101
2025 Q3	$201K	Buy	+2,003	New	+$180K	0.02%	116
2025 Q1	–	Sell	-2,302	Closed	-$207K	–	115
2024 Q4	$207K	Hold	2,302	–	–	0.03%	100
2024 Q3	$227K	Hold	2,302	–	–	0.04%	92
2024 Q2	$213K	Buy	+2,302	New	+$206K	0.04%	84
2022 Q2	–	Sell	-2,839	Closed	-$255K	–	82
2022 Q1	$255K	Buy	+2,839	New	+$262K	0.04%	63

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Sloy Dahl & Holst's XBI Position: Q2 2026 in Review

Sloy Dahl & Holst increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.05% in Q2 2026, buying an estimated $135 and bringing the position to 2,008 shares worth $318K. The position accounts for 0.04% of the portfolio, ranked #89.

Sloy Dahl & Holst first reported a position in XBI in Q1 2022 and has held it in 8 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Sloy Dahl & Holst held 2,008 shares of State Street SPDR S&P Biotech ETF worth $318K as of Q2 2026.
Sloy Dahl & Holst bought 1 State Street SPDR S&P Biotech ETF share in Q2 2026, an estimated $135.
State Street SPDR S&P Biotech ETF made up 0.04% of Sloy Dahl & Holst's portfolio in Q2 2026, its #89 holding.
Sloy Dahl & Holst first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 8 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Sloy Dahl & Holst's 13F filing for Q2 2026, filed 13 Aug 2026.